对热响应性向和功能疗法进行综合审查,用于治疗类风湿性关节炎
Huma Hameed1, Syed Sharf Ud Din2, Muhammad Zaman2
1Faculty of Pharmaceutical Sciences, University of Central Punjab, Lahore, 54000, Pakistan. huma.hameed@ucp.edu.pk.
Naunyn-Schmiedeberg's archives of pharmacology
|February 25, 2026
概括
结合治疗类风湿性关节炎 (RA) 使用甲状腺素 (MTX) 和其他药物显示效率提高,副作用比单独使用MTX更少. 先进的药物输送系统为RA提供了有前途的新治疗方案.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药物输送系统 药物输送系统
背景情况:
- 类风湿性关节炎 (RA) 是一种普遍存在的自身免疫性疾病,在历史上治疗选择有限.
- 目前用于RA的甲索特雷克萨特 (MTX) 治疗有副作用和不完全的症状缓解.
- 药物输送科学的进步正在为RA提供新的治疗方法.
研究的目的:
- 为了评估类风湿性关节炎 (RA) 组合疗法的疗效,与单一的甲醇 (MTX) 疗法相比.
- 探索RA治疗的先进药物输送系统,重点是注射配方.
- 确定治疗策略,以减少不良影响和RA复发.
主要方法:
- 对MTX单疗与组合疗法的比较分析,包括因弗力西马布 (INF),戈利穆马布 (GOL),莱夫卢诺米德 (LEF),叶酸 (FA) 和阿扎西奥普林.
- 对RA的注射治疗方法的审查,重点是热响应向药物输送系统.
- 对以水凝为基础的注射剂进行局部药物输送的检查.
主要成果:
- 组合疗法 (MTX + INF/GOL/LEF/FA/azathioprine) 显示出优于MTX单一疗法的疗效.
- 组合疗法导致副作用较少,RA复发风险较低.
- 热响应注射水凝代表了RA药物输送的前沿方法.
结论:
- 组合疗法在治疗类风湿性关节炎方面比MTX单一疗法更有效.
- 先进的药物输送系统,特别是热反应性水凝,具有改善RA治疗的巨大潜力.
- 未来的RA疗法可能会从有针对性的注射配方中受益,以提高疗效和患者的治疗结果.
相关概念视频
T Cell Types and Functions
2.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.9K
Rheumatic Heart Disease III: Medical Management
420
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
420
Inflammatory Response
17.5K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
17.5K
Connective Tissue Cell Types
4.3K
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
4.3K
Inflammatory Bowel Disease IV: Pharmacological Management
860
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
860
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
658
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
658


